Effect of PACAP38/VIP on Migraineurs Measured by Magnetic Resonance
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine and compare the effect of pituitary adenylate
cyclase-activating polypeptide-38 (PACAP38) and vasoactive intestinal polypeptide (VIP) on
intracranial arteries and neuronal activity in patients with migraine without aura using a
high resolution magnetic resonance imaging (MRI), including MR angiography (MRA) and
functional MRI (fMRI).
MRA will be used to detect changes in intracranial artery circumferences before and after
PACAP38 and VIP.
fMRI will be used oo detect changes in blood-oxygenation-level-dependent-signal
(BOLD-signal).
PACAP38 but not VIP induces migraine like attacks in migraine patients. The migraine specific
drug sumatriptan will be given to relieve pain and the effect will also be registered using
MRA and fMRI.
Phase:
N/A
Details
Lead Sponsor:
Glostrup University Hospital, Copenhagen
Collaborators:
Bispebjerg Hospital Cool Sorption Foundation of 1988 Lundbeck Foundation University Hospital, Gentofte, Copenhagen